Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Finazzi, Maria Chiara  [Clear All Filters]
2024
Finazzi MChiara, Weber A, Pavoni C, Grassi A, Micò MCaterina, Algarotti A, Lussana F, Rambaldi A. Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation. Bone Marrow Transplant. 2024.
2023
Hernández-Boluda JCarlos, Eikema D-J, Koster L, Kröger N, Robin M, de Witte M, Finke J, Finazzi MChiara, Broers A, Raida L, et al. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT. Bone Marrow Transplant. 2023.
Ortí G, Gras L, Zinger N, Finazzi MChiara, Sockel K, Robin M, Forcade E, Avenoso D, Kröger N, Finke J, et al. Outcomes after Allogeneic Hematopoietic Cell Transplant in patients diagnosed with Blast Phase of Myeloproliferative Neoplasms: a retrospective study from the Chronic Malignancies Working Party of the EBMT. Am J Hematol. 2023.
2019
Maffioli M, Giorgino T, Mora B, Iurlo A, Elli E, Finazzi MChiara, Caramella M, Rumi E, Carraro MCristina, Polverelli N, et al. Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. Blood Adv. 2019;3(21):3196-3200.
2018
Patriarca F, Masciulli A, Bacigalupo A, Bregante S, Pavoni C, Finazzi MChiara, Bosi A, Russo D, Narni F, Messina G, et al. Busulfan or thiotepa based conditioning in myelofibrosis: a phase II multicenter randomized study from the GITMO group. Biol Blood Marrow Transplant. 2018.